1.1.................... moves to amend S.F. No. 3322, the second engrossment, as follows:
1.2Page 453, after line 3, insert:


1.5    Section 1. Minnesota Statutes 2018, section 152.01, subdivision 23, is amended to read:
1.6    Subd. 23. Analog. (a) Except as provided in paragraph (b), "analog" means a substance,
1.7the chemical structure of which is substantially similar to the chemical structure of a
1.8controlled substance in Schedule I or II:
1.9(1) that has a stimulant, depressant, or hallucinogenic effect on the central nervous system
1.10that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic
1.11effect on the central nervous system of a controlled substance in Schedule I or II; or
1.12(2) with respect to a particular person, if the person represents or intends that the substance
1.13have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is
1.14substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect
1.15on the central nervous system of a controlled substance in Schedule I or II.
1.16(b) "Analog" does not include:
1.17(1) a controlled substance;
1.18(2) any substance for which there is an approved new drug application under the Federal
1.19Food, Drug, and Cosmetic Act; or
1.20(3) with respect to a particular person, any substance, if an exemption is in effect for
1.21investigational use, for that person, as provided by United States Code, title 21, section 355,
1.22and the person is registered as a controlled substance researcher as required under section
2.1152.12, subdivision 3, to the extent conduct with respect to the substance is pursuant to the
2.2exemption and registration; or
2.3(4) marijuana or tetrahydrocannabinols naturally contained in a plant of the genus
2.4cannabis or in the resinous extractives of the plant.
2.5EFFECTIVE DATE.This section is effective August 1, 2020, and applies to crimes
2.6committed on or after that date.

2.7    Sec. 2. Minnesota Statutes 2018, section 152.02, subdivision 2, is amended to read:
2.8    Subd. 2. Schedule I. (a) Schedule I consists of the substances listed in this subdivision.
2.9(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the
2.10following substances, including their analogs, isomers, esters, ethers, salts, and salts of
2.11isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers,
2.12and salts is possible:
2.13(1) acetylmethadol;
2.14(2) allylprodine;
2.15(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl
2.16acetate);
2.17(4) alphameprodine;
2.18(5) alphamethadol;
2.19(6) alpha-methylfentanyl benzethidine;
2.20(7) betacetylmethadol;
2.21(8) betameprodine;
2.22(9) betamethadol;
2.23(10) betaprodine;
2.24(11) clonitazene;
2.25(12) dextromoramide;
2.26(13) diampromide;
2.27(14) diethyliambutene;
2.28(15) difenoxin;
2.29(16) dimenoxadol;
3.1(17) dimepheptanol;
3.2(18) dimethyliambutene;
3.3(19) dioxaphetyl butyrate;
3.4(20) dipipanone;
3.5(21) ethylmethylthiambutene;
3.6(22) etonitazene;
3.7(23) etoxeridine;
3.8(24) furethidine;
3.9(25) hydroxypethidine;
3.10(26) ketobemidone;
3.11(27) levomoramide;
3.12(28) levophenacylmorphan;
3.13(29) 3-methylfentanyl;
3.14(30) acetyl-alpha-methylfentanyl;
3.15(31) alpha-methylthiofentanyl;
3.16(32) benzylfentanyl beta-hydroxyfentanyl;
3.17(33) beta-hydroxy-3-methylfentanyl;
3.18(34) 3-methylthiofentanyl;
3.19(35) thenylfentanyl;
3.20(36) thiofentanyl;
3.21(37) para-fluorofentanyl;
3.22(38) morpheridine;
3.23(39) 1-methyl-4-phenyl-4-propionoxypiperidine;
3.24(40) noracymethadol;
3.25(41) norlevorphanol;
3.26(42) normethadone;
3.27(43) norpipanone;
4.1(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
4.2(45) phenadoxone;
4.3(46) phenampromide;
4.4(47) phenomorphan;
4.5(48) phenoperidine;
4.6(49) piritramide;
4.7(50) proheptazine;
4.8(51) properidine;
4.9(52) propiram;
4.10(53) racemoramide;
4.11(54) tilidine;
4.12(55) trimeperidine;
4.13(56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
4.14(57) 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-
4.15methylbenzamide(U47700);
4.16(58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl);
4.17and
4.18(59) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol).
4.19(c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
4.20and salts of isomers, unless specifically excepted or unless listed in another schedule,
4.21whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
4.22(1) acetorphine;
4.23(2) acetyldihydrocodeine;
4.24(3) benzylmorphine;
4.25(4) codeine methylbromide;
4.26(5) codeine-n-oxide;
4.27(6) cyprenorphine;
4.28(7) desomorphine;
5.1(8) dihydromorphine;
5.2(9) drotebanol;
5.3(10) etorphine;
5.4(11) heroin;
5.5(12) hydromorphinol;
5.6(13) methyldesorphine;
5.7(14) methyldihydromorphine;
5.8(15) morphine methylbromide;
5.9(16) morphine methylsulfonate;
5.10(17) morphine-n-oxide;
5.11(18) myrophine;
5.12(19) nicocodeine;
5.13(20) nicomorphine;
5.14(21) normorphine;
5.15(22) pholcodine; and
5.16(23) thebacon.
5.17(d) Hallucinogens. Any material, compound, mixture or preparation which contains any
5.18quantity of the following substances, their analogs, salts, isomers (whether optical, positional,
5.19or geometric), and salts of isomers, unless specifically excepted or unless listed in another
5.20schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is
5.21possible:
5.22(1) methylenedioxy amphetamine;
5.23(2) methylenedioxymethamphetamine;
5.24(3) methylenedioxy-N-ethylamphetamine (MDEA);
5.25(4) n-hydroxy-methylenedioxyamphetamine;
5.26(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
5.27(6) 2,5-dimethoxyamphetamine (2,5-DMA);
5.28(7) 4-methoxyamphetamine;
6.1(8) 5-methoxy-3, 4-methylenedioxyamphetamine;
6.2(9) alpha-ethyltryptamine;
6.3(10) bufotenine;
6.4(11) diethyltryptamine;
6.5(12) dimethyltryptamine;
6.6(13) 3,4,5-trimethoxyamphetamine;
6.7(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
6.8(15) ibogaine;
6.9(16) lysergic acid diethylamide (LSD);
6.10(17) mescaline;
6.11(18) parahexyl;
6.12(19) N-ethyl-3-piperidyl benzilate;
6.13(20) N-methyl-3-piperidyl benzilate;
6.14(21) psilocybin;
6.15(22) psilocyn;
6.16(23) tenocyclidine (TPCP or TCP);
6.17(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
6.18(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
6.19(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
6.20(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
6.21(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
6.22(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
6.23(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
6.24(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
6.25(32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
6.26(33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
6.27(34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
7.1(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
7.2(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
7.3(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
7.4(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
7.5(2-CB-FLY);
7.6(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
7.7(40) alpha-methyltryptamine (AMT);
7.8(41) N,N-diisopropyltryptamine (DiPT);
7.9(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
7.10(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
7.11(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
7.12(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
7.13(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
7.14(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
7.15(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
7.16(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);
7.17(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
7.18(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
7.19(52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
7.20(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);
7.21(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
7.22(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
7.23(56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
7.24(57) methoxetamine (MXE);
7.25(58) 5-iodo-2-aminoindane (5-IAI);
7.26(59) 5,6-methylenedioxy-2-aminoindane (MDAI);
7.27(60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
8.1(61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
8.2(62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);
8.3(63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
8.4(64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
8.5(65) N,N-Dipropyltryptamine (DPT);
8.6(66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
8.7(67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
8.8(68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
8.9(69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
8.10(70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine,
8.11ethketamine, NENK);
8.12(71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);
8.13(72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and
8.14(73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).
8.15(e) Peyote. All parts of the plant presently classified botanically as Lophophora williamsii
8.16Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant,
8.17and every compound, manufacture, salts, derivative, mixture, or preparation of the plant,
8.18its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not
8.19apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian
8.20Church, and members of the American Indian Church are exempt from registration. Any
8.21person who manufactures peyote for or distributes peyote to the American Indian Church,
8.22however, is required to obtain federal registration annually and to comply with all other
8.23requirements of law.
8.24(f) Central nervous system depressants. Unless specifically excepted or unless listed in
8.25another schedule, any material compound, mixture, or preparation which contains any
8.26quantity of the following substances, their analogs, salts, isomers, and salts of isomers
8.27whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
8.28(1) mecloqualone;
8.29(2) methaqualone;
8.30(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
9.1(4) flunitrazepam; and
9.2(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine,
9.3methoxyketamine).
9.4(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any
9.5material compound, mixture, or preparation which contains any quantity of the following
9.6substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the
9.7analogs, salts, isomers, and salts of isomers is possible:
9.8    (1) aminorex;
9.9(2) cathinone;
9.10(3) fenethylline;
9.11    (4) methcathinone;
9.12(5) methylaminorex;
9.13(6) N,N-dimethylamphetamine;
9.14(7) N-benzylpiperazine (BZP);
9.15(8) methylmethcathinone (mephedrone);
9.16(9) 3,4-methylenedioxy-N-methylcathinone (methylone);
9.17(10) methoxymethcathinone (methedrone);
9.18(11) methylenedioxypyrovalerone (MDPV);
9.19(12) 3-fluoro-N-methylcathinone (3-FMC);
9.20(13) methylethcathinone (MEC);
9.21(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
9.22(15) dimethylmethcathinone (DMMC);
9.23(16) fluoroamphetamine;
9.24(17) fluoromethamphetamine;
9.25(18) α-methylaminobutyrophenone (MABP or buphedrone);
9.26(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
9.27(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
10.1(21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or
10.2naphyrone);
10.3(22) (alpha-pyrrolidinopentiophenone (alpha-PVP);
10.4(23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
10.5(24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
10.6(25) 4-methyl-N-ethylcathinone (4-MEC);
10.7(26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
10.8(27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
10.9(28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
10.10(29) 4-fluoro-N-methylcathinone (4-FMC);
10.11(30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
10.12(31) alpha-pyrrolidinobutiophenone (α-PBP);
10.13(32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
10.14(33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
10.15(34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
10.16(35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
10.17(36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
10.18(37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
10.19(38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP); and
10.20(39) any other substance, except bupropion or compounds listed under a different
10.21schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the
10.221-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the
10.23compound is further modified in any of the following ways:
10.24(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
10.25haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
10.26system by one or more other univalent substituents;
10.27(ii) by substitution at the 3-position with an acyclic alkyl substituent;
10.28(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
10.29methoxybenzyl groups; or
11.1(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
11.2(h) Marijuana, Synthetic tetrahydrocannabinols, and synthetic cannabinoids. Unless
11.3specifically excepted or unless listed in another schedule, any natural or synthetic material,
11.4compound, mixture, or preparation that contains any quantity of the following substances,
11.5their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever
11.6the existence of the isomers, esters, ethers, or salts is possible:
11.7(1) marijuana;
11.8(2) synthetic tetrahydrocannabinols naturally contained in a plant of the genus Cannabis,
11.9that are the synthetic equivalents of the substances contained in the cannabis plant or in the
11.10resinous extractives of the plant, or synthetic substances with similar chemical structure
11.11and pharmacological activity to those substances contained in the plant or resinous extract,
11.12including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans
11.13tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol;
11.14(3) (2) synthetic cannabinoids, including the following substances:
11.15(i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole
11.16structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
11.17alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
11.182-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
11.19extent and whether or not substituted in the naphthyl ring to any extent. Examples of
11.20naphthoylindoles include, but are not limited to:
11.21(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
11.22(B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);
11.23(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
11.24(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
11.25(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
11.26(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
11.27(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
11.28(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
11.29(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
11.30(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
12.1(ii) Napthylmethylindoles, which are any compounds containing a
12.21H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the
12.3indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
12.41-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
12.5substituted in the indole ring to any extent and whether or not substituted in the naphthyl
12.6ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:
12.7(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
12.8(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).
12.9(iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole
12.10structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
12.11alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
12.122-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any
12.13extent, whether or not substituted in the naphthyl ring to any extent. Examples of
12.14naphthoylpyrroles include, but are not limited to,
12.15(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
12.16(iv) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene
12.17structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl,
12.18cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
12.192-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any
12.20extent, whether or not substituted in the naphthyl ring to any extent. Examples of
12.21naphthylemethylindenes include, but are not limited to,
12.22E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
12.23(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole
12.24structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
12.25alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
12.262-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
12.27extent, whether or not substituted in the phenyl ring to any extent. Examples of
12.28phenylacetylindoles include, but are not limited to:
12.29(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
12.30(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
12.31(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
12.32(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
13.1(vi) Cyclohexylphenols, which are compounds containing a
13.22-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic
13.3ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
13.41-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted
13.5in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not
13.6limited to:
13.7(A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
13.8(B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
13.9(Cannabicyclohexanol or CP 47,497 C8 homologue);
13.10(C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
13.11-phenol (CP 55,940).
13.12(vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure
13.13with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,
13.14cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
13.152-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
13.16extent and whether or not substituted in the phenyl ring to any extent. Examples of
13.17benzoylindoles include, but are not limited to:
13.18(A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
13.19(B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
13.20(C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (WIN
13.2148,098 or Pravadoline).
13.22(viii) Others specifically named:
13.23(A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
13.24-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
13.25(B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
13.26-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
13.27(C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
13.28-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);
13.29(D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
13.30(E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
13.31(XLR-11);
14.1(F) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide
14.2(AKB-48(APINACA));
14.3(G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
14.4(5-Fluoro-AKB-48);
14.5(H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
14.6(I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro PB-22);
14.7(J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole- 3-carboxamide
14.8(AB-PINACA);
14.9(K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
14.101H-indazole-3-carboxamide (AB-FUBINACA);
14.11(L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-
14.12indazole-3-carboxamide(AB-CHMINACA);
14.13(M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3- methylbutanoate
14.14(5-fluoro-AMB);
14.15(N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
14.16(O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone)
14.17(FUBIMINA);
14.18(P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo
14.19[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
14.20(Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)
14.21-1H-indole-3-carboxamide (5-fluoro-ABICA);
14.22(R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
14.23-1H-indole-3-carboxamide;
14.24(S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
14.25-1H-indazole-3-carboxamide;
14.26(T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-dimethylbutanoate;
14.27(U) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1
14.28H-indazole-3-carboxamide (MAB-CHMINACA);
14.29(V) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide
14.30(ADB-PINACA);
15.1(W) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);
15.2(X) N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-
15.33-carboxamide. (APP-CHMINACA);
15.4(Y) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and
15.5(Z) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).
15.6(i) A controlled substance analog, to the extent that it is implicitly or explicitly intended
15.7for human consumption.
15.8EFFECTIVE DATE.This section is effective August 1, 2020, and applies to crimes
15.9committed on or after that date.

15.10    Sec. 3. Minnesota Statutes 2018, section 152.02, subdivision 3, is amended to read:
15.11    Subd. 3. Schedule II. (a) Schedule II consists of the substances listed in this subdivision.
15.12(b) Unless specifically excepted or unless listed in another schedule, any of the following
15.13substances whether produced directly or indirectly by extraction from substances of vegetable
15.14origin or independently by means of chemical synthesis, or by a combination of extraction
15.15and chemical synthesis:
15.16(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
15.17opiate.
15.18(i) Excluding:
15.19(A) apomorphine;
15.20(B) thebaine-derived butorphanol;
15.21(C) dextrophan;
15.22(D) nalbuphine;
15.23(E) nalmefene;
15.24(F) naloxegol;
15.25(G) naloxone;
15.26(H) naltrexone; and
15.27(I) their respective salts;
15.28(ii) but including the following:
15.29(A) opium, in all forms and extracts;
16.1(B) codeine;
16.2(C) dihydroetorphine;
16.3(D) ethylmorphine;
16.4(E) etorphine hydrochloride;
16.5(F) hydrocodone;
16.6(G) hydromorphone;
16.7(H) metopon;
16.8(I) morphine;
16.9(J) oxycodone;
16.10(K) oxymorphone;
16.11(L) thebaine;
16.12(M) oripavine;
16.13(2) any salt, compound, derivative, or preparation thereof which is chemically equivalent
16.14or identical with any of the substances referred to in clause (1), except that these substances
16.15shall not include the isoquinoline alkaloids of opium;
16.16(3) opium poppy and poppy straw;
16.17(4) coca leaves and any salt, cocaine compound, derivative, or preparation of coca leaves
16.18(including cocaine and ecgonine and their salts, isomers, derivatives, and salts of isomers
16.19and derivatives), and any salt, compound, derivative, or preparation thereof which is
16.20chemically equivalent or identical with any of these substances, except that the substances
16.21shall not include decocainized coca leaves or extraction of coca leaves, which extractions
16.22do not contain cocaine or ecgonine;
16.23(5) concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid,
16.24or powder form which contains the phenanthrene alkaloids of the opium poppy).
16.25(c) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
16.26of isomers, esters and ethers, unless specifically excepted, or unless listed in another schedule,
16.27whenever the existence of such isomers, esters, ethers and salts is possible within the specific
16.28chemical designation:
16.29(1) alfentanil;
16.30(2) alphaprodine;
17.1(3) anileridine;
17.2(4) bezitramide;
17.3(5) bulk dextropropoxyphene (nondosage forms);
17.4(6) carfentanil;
17.5(7) dihydrocodeine;
17.6(8) dihydromorphinone;
17.7(9) diphenoxylate;
17.8(10) fentanyl;
17.9(11) isomethadone;
17.10(12) levo-alpha-acetylmethadol (LAAM);
17.11(13) levomethorphan;
17.12(14) levorphanol;
17.13(15) metazocine;
17.14(16) methadone;
17.15(17) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
17.16(18) moramide - intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic
17.17acid;
17.18(19) pethidine;
17.19(20) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;
17.20(21) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;
17.21(22) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
17.22(23) phenazocine;
17.23(24) piminodine;
17.24(25) racemethorphan;
17.25(26) racemorphan;
17.26(27) remifentanil;
17.27(28) sufentanil;
18.1(29) tapentadol;
18.2(30) 4-Anilino-N-phenethyl-4-piperidine (ANPP).
18.3(d) Unless specifically excepted or unless listed in another schedule, any material,
18.4compound, mixture, or preparation which contains any quantity of the following substances
18.5having a stimulant effect on the central nervous system:
18.6(1) amphetamine, its salts, optical isomers, and salts of its optical isomers;
18.7(2) methamphetamine, its salts, isomers, and salts of its isomers;
18.8(3) phenmetrazine and its salts;
18.9(4) methylphenidate;
18.10(5) lisdexamfetamine.
18.11(e) Unless specifically excepted or unless listed in another schedule, any material,
18.12compound, mixture, or preparation which contains any quantity of the following substances
18.13having a depressant effect on the central nervous system, including its salts, isomers, and
18.14salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible
18.15within the specific chemical designation:
18.16(1) amobarbital;
18.17(2) glutethimide;
18.18(3) secobarbital;
18.19(4) pentobarbital;
18.20(5) phencyclidine;
18.21(6) phencyclidine immediate precursors:
18.22(i) 1-phenylcyclohexylamine;
18.23(ii) 1-piperidinocyclohexanecarbonitrile;
18.24(7) phenylacetone.
18.25(f) Hallucinogenic substances Cannabis and cannabinoids:
18.26(1) nabilone;
18.27(2) unless specifically excepted or unless listed in another schedule, any natural material,
18.28compound, mixture, or preparation that contains any quantity of the following substances,
19.1their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever
19.2the existence of the isomers, esters, ethers, or salts is possible:
19.3(i) marijuana; and
19.4(ii) tetrahydrocannabinols naturally contained in a plant of the genus cannabis or in the
19.5resinous extractives of the plant.
19.6EFFECTIVE DATE.This section is effective August 1, 2020, and applies to crimes
19.7committed on or after that date.

19.8    Sec. 4. Minnesota Statutes 2018, section 152.11, is amended by adding a subdivision to
19.9read:
19.10    Subd. 5. Exception. References in this section to Schedule II controlled substances do
19.11not extend to marijuana or tetrahydrocannabinols.

19.12    Sec. 5. Minnesota Statutes 2018, section 152.12, is amended by adding a subdivision to
19.13read:
19.14    Subd. 6. Exception. References in this section to Schedule II controlled substances do
19.15not extend to marijuana or tetrahydrocannabinols.

19.16    Sec. 6. Minnesota Statutes 2018, section 152.125, subdivision 3, is amended to read:
19.17    Subd. 3. Limits on applicability. This section does not apply to:
19.18(1) a physician's treatment of an individual for chemical dependency resulting from the
19.19use of controlled substances in Schedules II to V of section 152.02;
19.20(2) the prescription or administration of controlled substances in Schedules II to V of
19.21section 152.02 to an individual whom the physician knows to be using the controlled
19.22substances for nontherapeutic purposes;
19.23(3) the prescription or administration of controlled substances in Schedules II to V of
19.24section 152.02 for the purpose of terminating the life of an individual having intractable
19.25pain; or
19.26(4) the prescription or administration of a controlled substance in Schedules II to V of
19.27section 152.02 that is not a controlled substance approved by the United States Food and
19.28Drug Administration for pain relief; or
19.29(5) the administration of medical cannabis under sections 152.21 to 152.37.

20.1    Sec. 7. Minnesota Statutes 2018, section 152.126, subdivision 1, is amended to read:
20.2    Subdivision 1. Definitions. (a) For purposes of this section, the terms defined in this
20.3subdivision have the meanings given.
20.4    (b) "Board" means the Minnesota State Board of Pharmacy established under chapter
20.5151.
20.6    (c) "Controlled substances" means those substances listed in section 152.02, subdivisions
20.73 to 6, and those substances defined by the board pursuant to section 152.02, subdivisions
20.87, 8, and 12. For the purposes of this section, controlled substances includes butalbital and
20.9gabapentin but does not include medical cannabis under sections 152.21 to 152.37.
20.10    (d) "Dispense" or "dispensing" has the meaning given in section 151.01, subdivision
20.1130. Dispensing does not include the direct administering of a controlled substance to a
20.12patient by a licensed health care professional.
20.13    (e) "Dispenser" means a person authorized by law to dispense a controlled substance,
20.14pursuant to a valid prescription. For the purposes of this section, a dispenser does not include
20.15a licensed hospital pharmacy that distributes controlled substances for inpatient hospital
20.16care or a veterinarian who is dispensing prescriptions under section 156.18.
20.17    (f) "Prescriber" means a licensed health care professional who is authorized to prescribe
20.18a controlled substance under section 152.12, subdivision 1 or 2.
20.19    (g) "Prescription" has the meaning given in section 151.01, subdivision 16a."
20.20Amend the title accordingly